Non-Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock


Monocytes: protagonists of infarct inflammation and repair after myocardial infarction.


Myocardial infarction (MI) is the most frequent cause of heart failure, which is an incapacitating disease with high prevalence and broad socioeconomic impact. In 2008 in the United States, 5.7 million people suffered from heart failure, and more than 287 000 people died.1 Timely revascularization of ischemic myocardium reduces acute infarct mortality, and current standard therapy with  blockers and angiotensin-converting enzyme (ACE) inhibitors curbs development of post-MI heart failure. For example, ACE inhibitor treatment reduced mortality from 25% to 20% in the Survival and Ventricular Enlargement (SAVE) trial.2 Although this is a major advance, long-term mortality remains high. The combination of reduced acute infarct mortality due to efficient acute care and insufficient options to treat infarct survivors chronically has contributed to an increased heart failure prevalence (Figure 1).

Authors: Nahrendorf M, Pittet MJ, Swirski FK
Journal: Circulation; 2010 Jun 08; 121(22) 2437-45. doi:10.1161/CIRCULATIONAHA.109.916346
Year: 2010
PubMed: PMID: 20530020 (Go to PubMed)